Trials / Completed
CompletedNCT02057172
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 254 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HM11260C | HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue) |
| DRUG | liraglutide | Liraglutide is a GLP-1 agonist. |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2014-10-01
- Completion
- 2014-12-01
- First posted
- 2014-02-06
- Last updated
- 2016-08-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02057172. Inclusion in this directory is not an endorsement.